Status: Not yet recruiting
Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer
This study aims to evaluate whether the combination of Megestrol Acetate at the initiation of Trastuzumab Deruxtecan (T-DXd) treatment can effectively prevent and alleviate T-DXd-related fatigue, thereby improving the quality of life for advanced breast cancer patients.
Participants needed: 132
Trial details
Phase: Phase 3Age: 18-75Biological sex: FemaleType: InterventionalSponsor: Sun Yat-sen UniversityUpdated: Apr 22, 2026Locations: 1
Eligibility criteria
Female, aged 18-75 years [+10]
Severe underlying disease, comorbidities, active infection, or severe metabolic... [+8]